Emergent BioSolutions (EBS) Interest Expenses (2011 - 2026)

Emergent BioSolutions' Interest Expenses history runs 16 years deep, the most recent figure standing at $13.1 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 21.56% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was $62.6 million, a 1.26% decrease from a year earlier, with the FY2025 full-year figure at $329.6 million, down 2.77% from the prior year.
• Interest Expenses declined to $13.1 million in Q1 2026 per EBS's latest filing, from $17.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $35.0 million in Q2 2025 and bottomed at $7.8 million in Q2 2022.
• The 5-year median for Interest Expenses is $16.7 million (2025), against an average of $17.7 million.
• Across the five-year window, Interest Expenses jumped 266.67% in 2023 and tumbled 57.87% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $12.8 million in 2022, then jumped by 69.53% to $21.7 million in 2023, then plunged by 31.8% to $14.8 million in 2024, then climbed by 18.92% to $17.6 million in 2025, then fell by 25.57% to $13.1 million in 2026.
• Per Business Quant, the three latest EBS Interest Expenses figures stand at $13.1 million (Q1 2026), $17.6 million (Q4 2025), and $15.2 million (Q3 2025).